Targeted therapies for CRC now focus on a few common pathways, including EGFR (cetuximab and panitumumab) and VEGF (bevacizumab), which can stimulate a number of downstream intracellular signaling pathways including the PI3K signaling pathway [51]. The gene discussed is VEGFA; the disease is colorectal carcinoma.